What is claimed is:

1. A TNFR25 agonist for use in a method of delaying acute rejection of a transplanted organ or tissue in a subject, wherein the TNFR25 agonist is a Tumor necrosis factor-like ligand 1A-Ig fusion TL1A-Ig fusion.

2. The TNFR25 agonist for use according to claim 1, wherein the TNFR25 agonist induces proliferation of CD4+FoxP3+ cells in the subject.

3. Use of a TNFR25 agonist in the manufacture of a medicament for delaying acute rejection of a transplanted organ or tissue in a subject, wherein the TNFR25 agonist is a TL1A-Ig fusion.

4. The use according to claim 3, wherein the TNFR25 agonist induces proliferation of CD4+FoxP3+ cells in the subject.